» Articles » PMID: 10518178

Compounds Containing Cytosolic Choline in the Basal Ganglia: a Potential Biological Marker of True Drug Response to Fluoxetine

Overview
Journal Am J Psychiatry
Specialty Psychiatry
Date 1999 Oct 13
PMID 10518178
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Studies have identified two types of antidepressant response: true drug response and placebo pattern response. This study examined the relationship between true drug response and choline-creatine ratios in the basal ganglia of depressed patients treated with fluoxetine.

Method: The authors evaluated drug-free outpatients with major depression before (N = 41) and after (N = 15) 8 weeks of fluoxetine treatment, 20 mg/day, by using proton magnetic resonance spectroscopy.

Results: There was a significant difference in the degree of change from baseline to week 8 in choline-creatine ratios between the true drug response group (N = 8) and the placebo pattern response/nonresponse group (N = 7); the true drug response patients had a 20% increase in choline-creatine ratios, and the placebo pattern response/nonresponse patients had a 12% decrease in choline-creatine ratios.

Conclusions: These data suggest that true drug response to fluoxetine treatment in depression may be associated with an increase in choline-creatine ratios in the basal ganglia.

Citing Articles

Brain metabolite levels in remitted psychotic depression with consideration of effects of antipsychotic medication.

Tani H, Moxon-Emre I, Forde N, Neufeld N, Bingham K, Whyte E Brain Imaging Behav. 2023; 18(1):117-129.

PMID: 37917311 PMC: 10844359. DOI: 10.1007/s11682-023-00807-0.


Evaluation of Transcranial Magnetic Stimulation Efficiency in Major Depressive Disorder Patients: A Magnetic Resonance Spectroscopy Study.

Erbay M, Porgali Zayman E, Gonenir Erbay L, Unal S Psychiatry Investig. 2019; 16(10):745-750.

PMID: 31550877 PMC: 6801313. DOI: 10.30773/pi.2019.07.17.3.


A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression.

Toniolo R, Silva M, Fernandes F, Amaral J, Dias R, Lafer B J Neural Transm (Vienna). 2017; 125(2):247-257.

PMID: 29177955 PMC: 5775367. DOI: 10.1007/s00702-017-1817-5.


Evaluating metabolites in patients with major depressive disorder who received mindfulness-based cognitive therapy and healthy controls using short echo MRSI at 7 Tesla.

Li Y, Jakary A, Gillung E, Eisendrath S, Nelson S, Mukherjee P MAGMA. 2016; 29(3):523-33.

PMID: 26861048 PMC: 4891376. DOI: 10.1007/s10334-016-0526-7.


A MRS study of metabolic alterations in the frontal white matter of major depressive disorder patients with the treatment of SSRIs.

Zhang Y, Han Y, Wang Y, Zhang Y, Li L, Jin E BMC Psychiatry. 2015; 15:99.

PMID: 25934495 PMC: 4458012. DOI: 10.1186/s12888-015-0489-7.